Abiopharma

🔍 Fisher David (Executive)

Company: Enova International, Inc. (ENVA)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 9,491 shares of Common stock, par value $0.00001 per share at $20.73 per share (Direct)
  Date: 2026-08-25 | Code: M | equity_swap_involved: false | shares_owned_after: 315,935.00 | transaction_form_type: 4
• Sold 9,491 shares of Common stock, par value $0.00001 per share at $244.0104 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 306,444.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 9,078 shares of Common stock, par value $0.00001 per share at $20.73 per share (Direct)
  Date: 2026-08-26 | Code: M | equity_swap_involved: false | shares_owned_after: 315,522.00 | transaction_form_type: 4
• Sold 9,078 shares of Common stock, par value $0.00001 per share at $239.1631 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 306,444.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 9,491 shares of Non-Qualified Stock Option (right to buy) with limited SAR at $20.73 per share (Derivative)
  Date: 2026-08-25 | Code: M | Expires: 2027-02-11 | equity_swap_involved: false | shares_owned_after: 175,191.00 | transaction_form_type: 4 | Footnotes: F4, F6
• Sold 9,078 shares of Non-Qualified Stock Option (right to buy) with limited SAR at $20.73 per share (Derivative)
  Date: 2026-08-26 | Code: M | Expires: 2027-02-11 | equity_swap_involved: false | shares_owned_after: 166,113.00 | transaction_form_type: 4 | Footnotes: F4, F6

Footnotes:

• F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan adopted on January 30, 2026.
• F2: This transaction was executed in multiple trades at prices ranging from $241.46 to $251.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer full information regarding the number of shares and the prices at which the transaction was effected.
• F3: This transaction was executed in multiple trades at prices ranging from $236.29 to $244.93. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer full information regarding the number of shares and the prices at which the transaction was effected.
• F4: The limited stock appreciation right ("SAR") and employee stock option were granted in tandem. Accordingly, the exercise of one results in the expiration of the other. The SAR may be exercised only during the period beginning on the first day following the date that a "Change in Control" of Issuer occurs (as defined in the related grant agreement) and ending on the thirtieth day following such date. Upon exercise, the grantee shall be able to receive an amount equal to the product computed by multiplying (i) the excess of the "Offer Value Per Share" over the exercise price of the underlying option by (ii) the number of shares with respect to which the SAR is being exercised; provided, that such amount shall only be payable in the event an "Offer" is made.
• F5: The "Offer Value Per Share" means the average selling price of Issuer's common stock during the period of 30 days ending on the date on which the SAR is exercised. "Offer" means any tender offer or exchange offer for outstanding shares of Issuer representing at least 30% of the total voting power of the stock of Issuer, or an offer to purchase assets from Issuer that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of Issuer, other than an offer made by Issuer.
• F6: The options vested in substantially equal one-third increments on each of the following dates: February 11, 2021, February 11, 2022, and February 11, 2023.